A review of the latest developments in personalising schizophrenia treatment with a spotlight on Long-acting injectable (LAI) antipsychotic medication. Professor Bazire will take a look at some of the newer formulations of LAIs recently approved or in development and how LAIs can be a positive service-user choice. Nicola Greenhalgh will review evidence pointing to better outcomes where LAIs are used earlier in the treatment pathway and thus provide a real alternative to oral treatment.
 

Stephen Bazire session’s details

The development of antipsychotic long-acting injections - from punishment to patient preference

The session will cover psychosis, its treatment, how and why LAIs can be life-savers, recent and imminent developments in the formulations available and why LAIs have become a positive service user choice.

Nicola Greenhalgh session’s details

What is the place for antipsychotic algorithms?  The Qaapaple conundrum

Long-acting antipsychotic injections have often been held back for people who struggle to adhere to oral antipsychotics, yet evidence points to better outcomes where they are used.  Is it time for us to follow Canada and look at how we can optimise treatment with antipsychotics earlier in treatment?
 

Speaker honorarium from ROVI.
Non-relevant declarations will be on the first slide.